Delivery of gene targeting siRNAs to breast cancer cells using a multifunctional peptide complex that promotes both

Jeffrey D Bjorge1,2, Andy Pang1,2, Donald J Fujita1,2

  • 1Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Plos One
|July 1, 2017
PubMed

Insights

Researchers developed peptide-based delivery systems for small-interfering RNA (siRNA) to target cancer cells. These complexes effectively deliver siRNA, reduce protein levels, and inhibit tumor growth, showing promise for cancer therapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Nanotechnology

Background:

  • RNA interference (RNAi) is crucial for studying gene function in diseases like cancer.
  • Small-interfering RNA (siRNA) requires specialized delivery agents for cellular uptake.
  • Existing delivery methods face challenges in cellular interior access.

Purpose of the Study:

  • To develop and optimize peptide-based delivery systems for siRNA in cancer research.
  • To evaluate the efficacy of targeted peptide-siRNA complexes in breast cancer cells.
  • To assess the potential of these complexes for therapeutic applications in cancer treatment.

Main Methods:

  • Designed and synthesized novel siRNA-binding peptides with targeting (iRGD, Lyp-1) and endosomal release motifs.
  • Formulated stable peptide/siRNA complexes, optimizing ratios and characterizing particle size (100-300 nm) via electron microscopy.
  • Assessed nuclease resistance, cellular uptake (confocal microscopy), protein knockdown, and functional effects on cancer cell growth (MDA-MB-231).

Main Results:

  • Optimized peptide/siRNA complexes formed stable nanoparticles with enhanced serum nuclease protection.
  • Complexes were efficiently internalized by breast cancer cells and localized in the cytoplasm.
  • Lyp-1 targeted peptide complexes showed superior knockdown in MDA-MB-231 cells; endosomal release peptide significantly boosted efficacy.
  • Simultaneous targeting of Stat3 and c-Myc suppressed anchorage-independent growth, indicating reduced tumorigenicity.

Conclusions:

  • Peptide-based siRNA delivery systems effectively deliver siRNA into breast cancer cells.
  • These complexes achieve significant protein knockdown and suppress the malignant phenotype.
  • The developed peptide/siRNA complexes represent promising vehicles for cancer characterization and potential treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
59
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51